Corcept Therapeutics price target raised to $70.50 from $61 at Ladenburg

Ladenburg raised the firm’s price target on Corcept Therapeutics to $70.50 from $61 and keeps a Buy rating on the shares. The company announced the Phase 3 GRACE relacorilant trial for patients with Cushing’s syndrome met the primary endpoint in the randomized withdrawal phase, the analyst tells investors in a research note. As a result, the firm increased its probability of success on relacorilant in Cushing’s syndrome to 55% from 40%.